- Email: [email protected]
The metastasis-promoting roles of extravasated platelet aggregation in pancreatic cancer and stroma
Vol. 219, No. 4S, October 2014
Scientific Poster Presentations: 2014 Clinical Congress
e171
increased overall survival for all PMP patients (p¼0.003), and to those receiving chemotherapy in PMP1 (p¼0.002), not in PMP2 and PMP3. TS and TP did not correlate to overall or median survival amongst PMP tiers.
Hirohisa Kitagawa, MD, Mark D Duncan, MD, FACS, John W Harmon, MD, FACS, Tetsuo Ohta Kanazawa University Hospital, Kanazawa, Japan and Johns Hopkins University, Baltimore, MD
CONCLUSIONS: TS and TP are not useful prognostic factors for survival or response to chemotherapy. As expected, PMP1 showed a lower proliferative index (Ki-67) than PMP2 and PMP3. Though similar proliferation rates were seen in PMP2 and PMP3, significantly worse outcomes were seen in PMP3. Increased proliferation is not sufficient to explain the aggressiveness of SRCs.
INTRODUCTION: The last decade has focused attention on the central role of platelets interacting with tumor cells and the immune system in promoting tumor progression and distant spread through release of growth factors, such as TGF-b, VEGF-A and PAI-1, into the tumor microenvironment. We focused on the metastasis-promoting roles of extravasated platelet aggregation (EPA) in pancreatic cancer and stroma.
Multimodality therapy with chemoradiotherapy using 5-FU plus nedaplatin followed by additional surgery for locally advanced esophageal squamous cell carcinoma Naoshi Kubo, MD, PhD, Masaichi Ohira, MD, Katsunobu Sakurai, MD, PhD, Kosei Hirakawa, MD, PhD Osaka City University, Osaka, Japan
METHODS: Resected pancreatic cancer specimens from 40 patients were used in this study. To examine the expression and localization of platelet aggregation and epithelial-mesenchymal transition (EMT) in cancer and stroma, CD42b (platelet aggregation), Snail1 (EMT) and E-cadherin (epithelial cell junction) were assessed by immunohistochemistry. We determined correlation of these expressions with clinical features and overall survival.
INTRODUCTION: The prognosis of patients with clinical T4 (cT4) esophageal squamous cell carcinoma (EC) is unfavorable. The effectiveness of additional surgery after chemoradiotherapy (CRT) is controversial if a residual tumor is present. Here, we retrospectively review short- and long-term results of multimodality therapy with CRT using 5-FU plus nedaplatin followed by additional surgery for patients with cT4 EC. METHODS: Ninety-one patients with cT4 EC were enrolled. The male: female ratio was 69:22, and the mean age was 63.4 years. Seven hundreds mg/m2 5-FU and 60 mg/m2 nedaplatin were administered on days 1 and 29. Two Gy/fraction was radiated concurrently to a total dose of 40-50 Gy. After completing the CRT, additional surgery was performed in cases in which the tumor could be curatively resected. RESULTS: Sixty (67%) cases responded to this CRT therapy, which included nine (10%) complete responses and 51 (57%) partial responses using the RECIST evaluation system. Forty-one (45%) of 91 patients underwent additional surgery to resect residual tumor. The overall 3 year survival rate and median survival time of all patients was 29.5% and 377 days, respectively. The 3 year survival rate in the CRT followed by surgery group was 52.4%, which were significantly higher (p < 0.01) than those in the CRT alone group (6.4%). According to multivariate analysis, the presence of additional surgery (HR 0.225, p< 0.01), clinical response of CRT (HR 0.427, p< 0.01) were significant prognostic factors. CONCLUSIONS: The additional surgery after CRT for the responders in cT4 EC patients may be effective treatment. The metastasis-promoting roles of extravasated platelet aggregation in pancreatic cancer and stroma Tomoharu Miyashita, Hidehiro Tajima, MD, PhD, Isamu Makino, MD, Histoshi HN Nakagawara, MD,
RESULTS: CD42b expression was clearly stained at the invasive front of the tumor which is the EMT portion in 73%, but not in the region of tubular formation. Snail1 and loss of E-cadherin expression were noted in 85% and 75% at the EMT portion. There was significant correlation between CD42b and Snail 1 or loss of Ecadherin expression (p¼0.02, 0.008). Kaplan-Meier survival analysis identified no prognostic impact of CD42b, Snail 1 and loss of E-cadherin expression on overall survival. CONCLUSIONS: We demonstrate that EPA is associated with the first step of formation of EMT. These data suggest a potential role for antiplatelet agents to suppress EMT and metastasis by changing the tumor microenvironment. Complications and readmissions after immediate breast reconstruction: the California experience Shaila Merchant, MD, Leanne Goldstein, DrPH, Laura L Kruper, MD, FACS City of Hope National Medical Center, Duarte, CA INTRODUCTION: Reconstruction rates after mastectomy have been increasing; however, little is known about hospital readmissions after these procedures. We evaluated rates of and risk factors for readmission after mastectomy and immediate reconstruction (IR). METHODS: Using the Healthcare Cost and Utilization Project California state database, we identified patients undergoing mastectomy only (M) or with IR for ductal carcinoma in situ and invasive breast cancer (2005 to 2009). IR consisted of tissue expander/ implant (TE/I) and autologous tissue (AT). Readmission rates and complications were compared using the chi-square test. Multivariate logistic regression analysis was used to determine predictors of readmission.
Scientific Poster Presentations: 2014 Clinical Congress
e171
increased overall survival for all PMP patients (p¼0.003), and to those receiving chemotherapy in PMP1 (p¼0.002), not in PMP2 and PMP3. TS and TP did not correlate to overall or median survival amongst PMP tiers.
Hirohisa Kitagawa, MD, Mark D Duncan, MD, FACS, John W Harmon, MD, FACS, Tetsuo Ohta Kanazawa University Hospital, Kanazawa, Japan and Johns Hopkins University, Baltimore, MD
CONCLUSIONS: TS and TP are not useful prognostic factors for survival or response to chemotherapy. As expected, PMP1 showed a lower proliferative index (Ki-67) than PMP2 and PMP3. Though similar proliferation rates were seen in PMP2 and PMP3, significantly worse outcomes were seen in PMP3. Increased proliferation is not sufficient to explain the aggressiveness of SRCs.
INTRODUCTION: The last decade has focused attention on the central role of platelets interacting with tumor cells and the immune system in promoting tumor progression and distant spread through release of growth factors, such as TGF-b, VEGF-A and PAI-1, into the tumor microenvironment. We focused on the metastasis-promoting roles of extravasated platelet aggregation (EPA) in pancreatic cancer and stroma.
Multimodality therapy with chemoradiotherapy using 5-FU plus nedaplatin followed by additional surgery for locally advanced esophageal squamous cell carcinoma Naoshi Kubo, MD, PhD, Masaichi Ohira, MD, Katsunobu Sakurai, MD, PhD, Kosei Hirakawa, MD, PhD Osaka City University, Osaka, Japan
METHODS: Resected pancreatic cancer specimens from 40 patients were used in this study. To examine the expression and localization of platelet aggregation and epithelial-mesenchymal transition (EMT) in cancer and stroma, CD42b (platelet aggregation), Snail1 (EMT) and E-cadherin (epithelial cell junction) were assessed by immunohistochemistry. We determined correlation of these expressions with clinical features and overall survival.
INTRODUCTION: The prognosis of patients with clinical T4 (cT4) esophageal squamous cell carcinoma (EC) is unfavorable. The effectiveness of additional surgery after chemoradiotherapy (CRT) is controversial if a residual tumor is present. Here, we retrospectively review short- and long-term results of multimodality therapy with CRT using 5-FU plus nedaplatin followed by additional surgery for patients with cT4 EC. METHODS: Ninety-one patients with cT4 EC were enrolled. The male: female ratio was 69:22, and the mean age was 63.4 years. Seven hundreds mg/m2 5-FU and 60 mg/m2 nedaplatin were administered on days 1 and 29. Two Gy/fraction was radiated concurrently to a total dose of 40-50 Gy. After completing the CRT, additional surgery was performed in cases in which the tumor could be curatively resected. RESULTS: Sixty (67%) cases responded to this CRT therapy, which included nine (10%) complete responses and 51 (57%) partial responses using the RECIST evaluation system. Forty-one (45%) of 91 patients underwent additional surgery to resect residual tumor. The overall 3 year survival rate and median survival time of all patients was 29.5% and 377 days, respectively. The 3 year survival rate in the CRT followed by surgery group was 52.4%, which were significantly higher (p < 0.01) than those in the CRT alone group (6.4%). According to multivariate analysis, the presence of additional surgery (HR 0.225, p< 0.01), clinical response of CRT (HR 0.427, p< 0.01) were significant prognostic factors. CONCLUSIONS: The additional surgery after CRT for the responders in cT4 EC patients may be effective treatment. The metastasis-promoting roles of extravasated platelet aggregation in pancreatic cancer and stroma Tomoharu Miyashita, Hidehiro Tajima, MD, PhD, Isamu Makino, MD, Histoshi HN Nakagawara, MD,
RESULTS: CD42b expression was clearly stained at the invasive front of the tumor which is the EMT portion in 73%, but not in the region of tubular formation. Snail1 and loss of E-cadherin expression were noted in 85% and 75% at the EMT portion. There was significant correlation between CD42b and Snail 1 or loss of Ecadherin expression (p¼0.02, 0.008). Kaplan-Meier survival analysis identified no prognostic impact of CD42b, Snail 1 and loss of E-cadherin expression on overall survival. CONCLUSIONS: We demonstrate that EPA is associated with the first step of formation of EMT. These data suggest a potential role for antiplatelet agents to suppress EMT and metastasis by changing the tumor microenvironment. Complications and readmissions after immediate breast reconstruction: the California experience Shaila Merchant, MD, Leanne Goldstein, DrPH, Laura L Kruper, MD, FACS City of Hope National Medical Center, Duarte, CA INTRODUCTION: Reconstruction rates after mastectomy have been increasing; however, little is known about hospital readmissions after these procedures. We evaluated rates of and risk factors for readmission after mastectomy and immediate reconstruction (IR). METHODS: Using the Healthcare Cost and Utilization Project California state database, we identified patients undergoing mastectomy only (M) or with IR for ductal carcinoma in situ and invasive breast cancer (2005 to 2009). IR consisted of tissue expander/ implant (TE/I) and autologous tissue (AT). Readmission rates and complications were compared using the chi-square test. Multivariate logistic regression analysis was used to determine predictors of readmission.